Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Krystal Biotech, Inc. Director's Dealing 2017

Sep 25, 2017

31006_dirs_2017-09-25_b6bee51f-fd78-4437-8fa1-51926cbe3878.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3/A — Form 3/A

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: Krishnan Suma (Director, Chief Operating Officer, 10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Convertible Preferred Stock $ Common Stock (112162) Indirect

Footnotes

F1: The Series A convertible preferred stock will automatically convert on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.

F2: These shares were incorrectly included in the Non-Derivative Securities table in the reporting person's original Form 3, filed September 19, 2017.

F3: The Krishnan Family Trust beneficially owns 112,162 shares of Series A convertible preferred stock. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control.